CN1371427A - Method for identifying individual at risk for vascular and cancer disease - Google Patents
Method for identifying individual at risk for vascular and cancer disease Download PDFInfo
- Publication number
- CN1371427A CN1371427A CN00812226A CN00812226A CN1371427A CN 1371427 A CN1371427 A CN 1371427A CN 00812226 A CN00812226 A CN 00812226A CN 00812226 A CN00812226 A CN 00812226A CN 1371427 A CN1371427 A CN 1371427A
- Authority
- CN
- China
- Prior art keywords
- concentration
- homocysteine
- serum
- analyte
- pepsinogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 206010028980 Neoplasm Diseases 0.000 title description 4
- 201000011510 cancer Diseases 0.000 title description 4
- 230000002792 vascular Effects 0.000 title 1
- 210000002966 serum Anatomy 0.000 claims abstract description 49
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims abstract description 39
- 108010047320 Pepsinogen A Proteins 0.000 claims abstract description 27
- 239000012491 analyte Substances 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims description 11
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 101710198144 Endopolygalacturonase I Proteins 0.000 claims description 4
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 238000012207 quantitative assay Methods 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 abstract description 6
- 201000011531 vascular cancer Diseases 0.000 abstract description 2
- 235000019156 vitamin B Nutrition 0.000 description 20
- 239000011720 vitamin B Substances 0.000 description 20
- 210000002784 stomach Anatomy 0.000 description 18
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 10
- 208000004300 Atrophic Gastritis Diseases 0.000 description 9
- 208000036495 Gastritis atrophic Diseases 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003113 dilution method Methods 0.000 description 4
- 108010066264 gastrin 17 Proteins 0.000 description 4
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 229940029329 intrinsic factor Drugs 0.000 description 4
- 201000000498 stomach carcinoma Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241000255640 Loa loa Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241000447394 Desmos Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI991836A FI107808B (en) | 1999-08-31 | 1999-08-31 | A method for identifying an individual at risk for vascular and cancerous disease |
FI19991836 | 1999-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1371427A true CN1371427A (en) | 2002-09-25 |
CN1158389C CN1158389C (en) | 2004-07-21 |
Family
ID=8555217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008122261A Expired - Lifetime CN1158389C (en) | 1999-08-31 | 2000-08-30 | Method for identifying individual at risk for vascular and cancer disease |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1210452A1 (en) |
JP (1) | JP2003508059A (en) |
CN (1) | CN1158389C (en) |
AU (1) | AU6845600A (en) |
FI (1) | FI107808B (en) |
RU (1) | RU2247389C2 (en) |
WO (1) | WO2001016356A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114924016A (en) * | 2022-04-28 | 2022-08-19 | 中国医学科学院北京协和医院 | Method for simultaneously detecting sulfated gastrin G17 and non-sulfated gastrin G17 and detection kit thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2453001C1 (en) * | 2010-10-18 | 2012-06-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Method for l-norvaline correction of hyperhomocystein induced nitrogen oxide deficiency in experiment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI97304C (en) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | A method for screening for the risk of gastric cancer |
-
1999
- 1999-08-31 FI FI991836A patent/FI107808B/en active
-
2000
- 2000-08-30 AU AU68456/00A patent/AU6845600A/en not_active Abandoned
- 2000-08-30 JP JP2001520901A patent/JP2003508059A/en active Pending
- 2000-08-30 WO PCT/FI2000/000733 patent/WO2001016356A1/en active Application Filing
- 2000-08-30 EP EP00956556A patent/EP1210452A1/en not_active Ceased
- 2000-08-30 CN CNB008122261A patent/CN1158389C/en not_active Expired - Lifetime
- 2000-08-30 RU RU2002107982/15A patent/RU2247389C2/en active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114924016A (en) * | 2022-04-28 | 2022-08-19 | 中国医学科学院北京协和医院 | Method for simultaneously detecting sulfated gastrin G17 and non-sulfated gastrin G17 and detection kit thereof |
CN114924016B (en) * | 2022-04-28 | 2024-03-08 | 中国医学科学院北京协和医院 | Method for simultaneously detecting sulfated and non-sulfated gastrin G17 and detection kit thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2001016356A1 (en) | 2001-03-08 |
FI19991836A (en) | 2001-02-28 |
EP1210452A1 (en) | 2002-06-05 |
CN1158389C (en) | 2004-07-21 |
FI107808B (en) | 2001-10-15 |
JP2003508059A (en) | 2003-03-04 |
RU2247389C2 (en) | 2005-02-27 |
AU6845600A (en) | 2001-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kyhse-Andersen et al. | Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate | |
Ueland et al. | Total homocysteine in plasma or serum: methods and clinical applications | |
US7749729B2 (en) | Methods for assessing the risk for development of cardiovascular disease | |
Kropf et al. | Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. | |
JP3646097B2 (en) | Reagents and solid phase components of specific binding assays that do not contain an advanced glycosylation end product | |
Niemelä | Radioimmunoassays for type III procollagen amino-terminal peptides in humans. | |
EP1418432B1 (en) | Method, assay, and kit for quantifying hiv protease inhibitors | |
Wang | Concentration of arsenic, selenium, zinc, iron and copper in the urine of blackfoot disease patients at different clinical stages | |
CN1158389C (en) | Method for identifying individual at risk for vascular and cancer disease | |
FI75935B (en) | FOERFARANDE FOER ANALYSISING AV KOMPLEMENTFRAGMENTET C3A, C4A OCH C5A ELLER DES-ARG DERIVAT OCH EN FOER UTFOERANDE AV FOERFARANDET ANVAENDBAR UPPSAETTNING. | |
CN107002017A (en) | The accurate measure measurement of hydrophobicity haptens analyte | |
Hjemdahl et al. | A new assay for β-thromboglobulin in urine | |
WO1997026534A1 (en) | Detection of cardiac muscle necrosis by immunoassay and appropriate antibodies therefor | |
US20090311719A1 (en) | In vitro method for diagnosing neurodegenerative diseases | |
Zappacosta et al. | Comparing different methods for homocysteine determination | |
CA2004387C (en) | Cyclosporine binding protein and use in an assay for biologically-active cyclosporine | |
Mourvaki et al. | Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease | |
CN109374904A (en) | A kind of protein-based sepsis markers and its in the application of severe sepsis early warning and its screening technique | |
Finglas et al. | Validity of dual-label stable isotopic protocols and urinary excretion ratios to determine folate bioavailability from food | |
Viglio et al. | The “history” of desmosines: Forty Years of debate on the hypothesis that these two unnatural amino acids may be potential biomarkers of chronic obstructive pulmonary disease | |
RU2224258C2 (en) | Method for identifying person with the risk of non reversible neurological lesions including stages for quantitative detection of pepsinogen i (pg i) and vitamin b 12 concentrations | |
Tóth et al. | Elevated levels of plasma and urine beta-thromboglobulin or thromboxane-B2 as markers of real platelet hyperactivation in diabetic nephropathy | |
JP2003508059A5 (en) | ||
Doncheva et al. | Study of homocysteine concentration in coronary heart disease patients and comparison of two determination methods | |
Pernet et al. | Plasma homocysteine measurement with ion exchange chromatography (Jeol Aminotac 500): a comparison with the Abbott IMx assay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BIOHIT BIOECH (HEFEI) CO., LTD. Free format text: FORMER OWNER: BIOHIT OY Effective date: 20141202 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 230000 HEFEI, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141202 Address after: 230000 Anhui Province, Hefei high tech Zone Wangjiang Road, No. 800 Hefei Innovation Industrial Park D9 building a layer to five Patentee after: Will Europe Han Biotechnology (Hefei) Co., Ltd. Address before: Helsinki Patentee before: Biohit OY |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161228 Address after: Helsinki Patentee after: Biohit OY Address before: 230000 Anhui Province, Hefei high tech Zone Wangjiang Road, No. 800 Hefei Innovation Industrial Park D9 building a layer to five Patentee before: Will Europe Han Biotechnology (Hefei) Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20020925 Assignee: Will Europe Han Biotechnology (Hefei) Co., Ltd. Assignor: Biohit OY Contract record no.: 2017990000359 Denomination of invention: Method for identifying individual at risk for vascular and cancer disease Granted publication date: 20040721 License type: Exclusive License Record date: 20170908 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CX01 | Expiry of patent term |
Granted publication date: 20040721 |
|
CX01 | Expiry of patent term |